S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
NASDAQ:GH

Guardant Health - GH Stock Forecast, Price & News

$31.48
+0.41 (+1.32%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$30.59
$31.88
50-Day Range
$25.44
$53.81
52-Week Range
$24.63
$78.34
Volume
1.00 million shs
Average Volume
1.45 million shs
Market Capitalization
$3.22 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$90.39

Guardant Health MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.94 Rating Score
Upside/​Downside
187.2% Upside
$90.39 Price Target
Short Interest
Bearish
5.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.95
Upright™ Environmental Score
News Sentiment
1.34mentions of Guardant Health in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$162,094 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.46) to ($5.19) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.71 out of 5 stars

Medical Sector

75th out of 1,049 stocks

Medical Laboratories Industry

3rd out of 25 stocks


GH stock logo

About Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

Receive GH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.

GH Stock News Headlines

The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Comparing Guardant Health (NASDAQ:GH) & MDxHealth (NASDAQ:MDXH)
GH.OQ - | Stock Price & Latest News | Reuters
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Guardant Health Looks Downright Sickly
Guardant Health Recent Insider Activity
Guardant Health Unusual Options Activity
Guardant: Saving Lives One Blood Test At A Time
GH Guardant Health, Inc.
East Jefferson General Hospital
See More Headlines
Receive GH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.

GH Company Calendar

Last Earnings
11/03/2022
Today
1/29/2023
Next Earnings (Estimated)
2/22/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Employees
1,373
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$90.39
High Stock Price Forecast
$165.00
Low Stock Price Forecast
$36.00
Forecasted Upside/Downside
+187.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.94
Research Coverage
16 Analysts

Profitability

Net Income
$-405,670,000.00
Net Margins
-140.58%
Pretax Margin
-136.14%

Debt

Sales & Book Value

Annual Sales
$373.65 million
Book Value
$6.34 per share

Miscellaneous

Free Float
96,392,000
Market Cap
$3.22 billion
Optionable
Not Optionable
Beta
0.83

Key Executives

  • Dr. Helmy Eltoukhy Ph.D. (Age 44)
    Co-Founder, Co-CEO & Chairman
    Comp: $13.66k
  • Dr. AmirAli Talasaz Ph.D. (Age 43)
    Co-CEO & Director
    Comp: $13.27k
  • Mr. Michael Bell (Age 54)
    Chief Financial Officer
    Comp: $1.2M
  • Mr. John G. Saia (Age 50)
    Chief Legal Officer
    Comp: $641.22k
  • Dr. Craig Eagle M.D. (Age 56)
    Chief Medical Officer
    Comp: $2.88M
  • Mr. Christopher Freeman (Age 49)
    Chief Commercial Officer of Oncology Bus.
    Comp: $740.23k
  • Mr. Andy Ament
    Sr. VP of Operations
  • Darya Chudova
    Sr. VP of Technology
  • Mr. Kumud  KaliaMr. Kumud Kalia
    Chief Information Officer
  • Ms. Jennifer Higgins
    VP of Public Affairs













GH Stock - Frequently Asked Questions

Should I buy or sell Guardant Health stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last twelve months. There are currently 1 hold rating and 15 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GH shares.
View GH analyst ratings
or view top-rated stocks.

What is Guardant Health's stock price forecast for 2023?

16 Wall Street analysts have issued 12-month price objectives for Guardant Health's stock. Their GH share price forecasts range from $36.00 to $165.00. On average, they anticipate the company's stock price to reach $90.39 in the next twelve months. This suggests a possible upside of 187.2% from the stock's current price.
View analysts price targets for GH
or view top-rated stocks among Wall Street analysts.

How have GH shares performed in 2023?

Guardant Health's stock was trading at $27.20 at the beginning of 2023. Since then, GH stock has increased by 15.7% and is now trading at $31.4750.
View the best growth stocks for 2023 here
.

When is Guardant Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our GH earnings forecast
.

How were Guardant Health's earnings last quarter?

Guardant Health, Inc. (NASDAQ:GH) issued its earnings results on Thursday, November, 3rd. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.27) by $0.31. The company earned $117.40 million during the quarter, compared to the consensus estimate of $118.18 million. Guardant Health had a negative net margin of 140.58% and a negative trailing twelve-month return on equity of 145.58%.

What guidance has Guardant Health issued on next quarter's earnings?

Guardant Health updated its FY 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $447.00 million-$450.00 million, compared to the consensus revenue estimate of $445.24 million.

What is Helmy Eltoukhy's approval rating as Guardant Health's CEO?

52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among the company's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Guardant Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Block (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).

When did Guardant Health IPO?

(GH) raised $200 million in an IPO on Thursday, October 4th 2018. The company issued 12,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

What is Guardant Health's stock symbol?

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Who are Guardant Health's major shareholders?

Guardant Health's stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (0.49%), Sicart Associates LLC (0.10%), Exchange Traded Concepts LLC (0.03%), Oak Ridge Investments LLC (0.02%), Values First Advisors Inc. (0.01%) and Xponance Inc. (0.01%). Insiders that own company stock include Amelia Merrill, Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Kumud Kalia, Michael J Wiley, Samir Kaul, Stanley J Meresman and Stanley J Meresman.
View institutional ownership trends
.

How do I buy shares of Guardant Health?

Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Guardant Health's stock price today?

One share of GH stock can currently be purchased for approximately $31.48.

How much money does Guardant Health make?

Guardant Health (NASDAQ:GH) has a market capitalization of $3.22 billion and generates $373.65 million in revenue each year. The company earns $-405,670,000.00 in net income (profit) each year or ($5.93) on an earnings per share basis.

How many employees does Guardant Health have?

The company employs 1,373 workers across the globe.

How can I contact Guardant Health?

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The official website for the company is www.guardanthealth.com. The company can be reached via phone at (855) 698-8887, via email at investors@guardanthealth.com, or via fax at 888-974-4258.

This page (NASDAQ:GH) was last updated on 1/29/2023 by MarketBeat.com Staff